Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
Although in vitro studies show that muscarinic M(3) receptors primarily mediate the effects of acetylcholine on gastrointestinal contractility, the muscarinic receptor subtypes regulating gastrointestinal motor activity and transit in humans in vivo are unclear. We hypothesized that muscarinic M(3)-specific but not nonspecific receptor antagonists would delay gastrointestinal and colonic transit in humans. In this parallel-group study, gastric emptying, small intestinal transit, and colonic transit were assessed by scintigraphy on days 4-6 in 72 healthy subjects (49 women) who received placebo (n = 16), the M(3) antagonist darifenacin ER [7.5 mg (n = 20) or 15 mg daily (n = 17)], or the nonspecific antagonist tolterodine [4 mg daily (n = 19)] for 6 days. Bowel habits were recorded by daily diaries. Both doses of darifenacin substantially delayed [P < 0.01 vs. placebo (for both doses), P < 0.01 vs. tolterodine (for 15 mg)] small intestinal transit, i.e., colonic filling at 6 h (placebo [59.6 +/- 6.4%, mean +/- SE], 7.5 mg ER [34.4 +/- 6.1%], 15 mg ER [20.4 +/- 6.3%)]. Darifenacin (15 mg) also delayed (P < 0.01 vs. placebo and tolterodine) half-time for ascending colonic emptying [placebo (12.0 +/- 1.5 h), 7.5 mg (18.6 +/- 1.9 h), 15 mg (22.9 +/- 2.6 h)] and colonic transit (geometric center) at 24 [placebo (2.8 +/- 0.2), 7.5 mg (2.4 +/- 0.2), 15 mg (1.9 +/- 0.2)] but not 48 h. Darifenacin did not affect gastric emptying and tolterodine did not affect bowel habits or gastrointestinal transit. With muscarinic antagonists used at clinically approved doses, these findings demonstrate that muscarinic M(3) receptors regulate small intestinal and colonic transit in humans; colonic effects are more pronounced in the right than left colon. At doses that affect small and large intestinal transit, M(3) antagonists do not affect gastric emptying in humans. The efficacy of darifenacin in diarrhea-predominant irritable bowel syndrome should be evaluated.
Bharucha
Adil E
AE
Clinical and Enteric Neuroscience Translational and Epidemiological Research Program (C.E.N.T.E.R.) Mayo Clinic and Mayo Foundation, 200 First St. S.W., Rochester, MN 55905, USA. bharucha.adil@mayo.edu
Ravi
Karthik
K
Zinsmeister
Alan R
AR
D000328:Adult; D001559:Benzhydryl Compounds / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects* / Q000378:metabolism; D003408:Cresols / Q000494:pharmacology*; D003672:Defecation / Q000187:drug effects*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D010665:Phenylpropanolamine / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013997:Time Factors; D000068737:Tolterodine Tartrate; D055815:Young Adult
D001559:Benzhydryl Compounds; D001572:Benzofurans; D003408:Cresols; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; D043587:Receptor, Muscarinic M3; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C101207:darifenacin
Gut. 1999 Sep;45(3):346-54
10446101
BJU Int. 2005 May;95(7):993-1001
15839920
Aliment Pharmacol Ther. 2004 Aug 1;20(3):355-64
15274673
Eur J Pharmacol. 2007 Jan 12;554(2-3):212-22
17113073
J Physiol. 2003 Jan 15;546(Pt 2):415-25
12527728
Urology. 2001 Mar;57(3):414-21
11248608
Clin Gastroenterol Hepatol. 2005 Aug;3(8):784-91
16234007
Naunyn Schmiedebergs Arch Pharmacol. 1995 Mar;351(3):237-43
7609776
Gastroenterology. 1989 Jan;96(1):116-21
2909418
Neurogastroenterol Motil. 2001 Dec;13(6):567-74
11903917
Neurogastroenterol Motil. 2008 Jun;20(6):643-8
18312543
J Neurophysiol. 2005 May;93(5):2841-8
15574798
Gastroenterology. 1991 Jul;101(1):107-15
2044899
Br J Pharmacol. 2006 Jul;148(5):565-78
16751797
Life Sci. 1997;60(13-14):1053-60
9121347
Am J Gastroenterol. 2006 Mar;101(3):604-12
16464225
Urology. 2006 Feb;67(2):275-80
16461077
Prog Histochem Cytochem. 2010 Feb;44(4):173-202
20159236
Neurogastroenterol Motil. 2002 Oct;14(5):535-41
12358682
Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90
12269971
Clin Gastroenterol Hepatol. 2008 Jul;6(7):772-81
18456567
Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):463-71
18074121
J Physiol. 1985 Nov;368:435-52
4078746
Gen Pharmacol. 1990;21(1):17-21
2298386
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
6880820
Drugs. 1985 Aug;30(2):85-126
3928324
Am J Gastroenterol. 2001 Sep;96(9):2671-6
11569693
Trends Pharmacol Sci. 2001 Aug;22(8):409-14
11479003
J Pharmacol Exp Ther. 1993 Feb;264(2):789-94
8437127
Gastroenterology. 1985 Sep;89(3):562-70
4018502
Aliment Pharmacol Ther. 1997 Jun;11(3):561-8
9218083
Br J Pharmacol. 1988 Mar;93(3):715-20
3370394
Aliment Pharmacol Ther. 2000 Jul;14(7):869-78
10886042